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Abstract
Background: Management of febrile neutropenic episodes (FE) is challenged by lacking microbiological and clinical
documentation of infection. We aimed at evaluating the utility of monitoring blood procalcitonin (PCT) in FE for initial
diagnosis of infection and reassessment in persistent fever.
Methods: PCT kinetics was prospectively monitored in 194 consecutive FE (1771 blood samples): 65 microbiologically
documented infections (MDI, 33.5%; 49 due to non-coagulase-negative staphylococci, non-CNS), 68 clinically documented
infections (CDI, 35%; 39 deep-seated), and 61 fever of unexplained origin (FUO, 31.5%).
Results: At fever onset median PCT was 190 pg/mL (range 30–26’800), without significant difference among MDI, CDI and
FUO. PCT peak occurred on day 2 after onset of fever: non-CNS-MDI/deep-seated-CDI (656, 80–86350) vs. FUO (205, 33–771;
p,0.001). PCT .500 pg/mL distinguished non-CNS-MDI/deep-seated-CDI from FUO with 56% sensitivity and 90%
specificity. PCT was .500 pg/ml in only 10% of FUO (688, 570–771). A PCT peak .500 pg/mL (1196, 524–11950) occurred
beyond 3 days of persistent fever in 17/21 (81%) invasive fungal diseases (IFD). This late PCT peak identified IFD with 81%
sensitivity and 57% specificity and preceded diagnosis according to EORTC-MSG criteria in 41% of cases. In IFD responding
to therapy, median days to PCT ,500 pg/mL and defervescence were 5 (1–23) vs. 10 (3–22; p=0.026), respectively.
Conclusion: While procalcitonin is not useful for diagnosis of infection at onset of neutropenic fever, it may help to
distinguish a minority of potentially severe infections among FUOs on day 2 after onset of fever. In persistent fever
monitoring procalcitonin contributes to early diagnosis and follow-up of invasive mycoses.
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Introduction
Febrile neutropenia is a frequent complication in patients with
hematological malignancies requiring prompt empirical broad-
spectrum antibacterial therapy. Cultures and clinical examination
fail to detect a pathogen and/or an infectious focus in 30–60% of
episodes, which are classified as fever of unknown origin (FUO)
[1]. As infectious and non-infectious etiologies of FUO cannot be
differentiated, all patients receive maybe unnecessarily prolonged
empirical antibacterial therapy. Persistence of fever despite
ongoing antibiotics may suggest uncontrolled and potentially life-
threatening infection due to resistant bacteria or fungi. Unresolved
fever represents a major challenge for diagnosis and therapy, often
resulting in multiple investigations and empirical modifications of
antibacterial and/or addition of antifungal therapy [1]. New
diagnostic tools are thus needed for guiding management of febrile
neutropenic patients when initial microbiological and clinical
documentation is lacking and in persistent fever, when resistant
bacterial infection or invasive fungal disease (IFD) is suspected.
Procalcitonin (PCT) is a prohormone of calcitonin produced
during systemic infection in response to circulating microbial
toxins and host inflammatory mediators [2,3]. Previous studies in
non-neutropenic patients have reported the utility of PCT for
differentiating bacterial from viral infections or non-infectious
inflammatory conditions [2,3,4,5,6]. PCT concentrations thresh-
olds have been proposed for distinguishing systemic from localized
infections and infections due to virulent pathogens from those due
to pathogens with low virulence (e.g. coagulase-negative staphy-
lococci, CNS). Christ-Crain et al have shown that a PCT-based
management algorithm reduces antibiotic use in lower respiratory
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18886tract infections [7,8]. A high variability of the diagnostic
performance of PCT has been reported in febrile neutropenic
patients, in whom the utility of this blood marker remains unclear
[9]. Few data are available on PCT in persistent neutropenic fever
and suspected IFD. We aimed at prospectively monitoring the
PCT kinetics in febrile neutropenic patients for the initial
assessment of the etiology of fever and the diagnostic reassessment
in persistent fever.
Methods
Patients
This study was conducted in the Isolation Ward of the
Infectious Diseases Service of a 900-bed University Hospital
during an 18-month period. Consecutive adult patients undergo-
ing induction or consolidation myelosuppressive chemotherapy for
acute leukemia, or intensive chemotherapy followed by autologous
hematopoietic peripheral stem cell transplantation were enrolled
after written informed-consent. All patients were hospitalized in
single-bed isolation rooms with positive pressure and HEPA-
filtered ventilation. The protocol was reviewed and accepted by
the local HREC (Commission d’e ´thique de la recherche clinique,
Faculte ´d eM e ´decine et de Biologie, Universite ´ de Lausanne,
approval number 179/01 on the 5th November 2001). All patients
gave written informed consent prior to study enrolment.
Febrile episodes
Neutropenia was defined as a neutrophil count ,500/mm
3.A
febrile neutropenic episode (FE) was defined as an axillary
temperature .38.5uC once or $38uC on two or more occasions
(at least one hour apart) during a 12-h period [1]. A new febrile
episode was defined as a relapsing fever after more than 72 hours
of apyrexia (,38uC). For each FE the initial diagnostic work-up
consisted of a thorough physical examination, two sets of aerobic
and anaerobic blood cultures drawn by phlebotomy and via each
line of the central venous catheter, urine culture, and chest X-ray.
Additional specific investigations were performed according to the
clinical presentation (e.g.: PCR for HSV on oropharyngeal swabs
in patients with severe mucositis, screening of respiratory viruses
with specific PCRs in patients with suggestive symptoms/signs). In
persistent fever during more than 3 days, the diagnostic
reassessment included repeated blood cultures as described above,
2-weekly measurement of galactomannan antigenemia (results
were not available in real-time for clinical decisions, and only used
for diagnostic classification of IFD: see next paragraph), a thoraco-
abdominal CT-scan, a bronchoscopy with BAL in presence of a
lung infiltrate, and biopsy for culture and histopathology at any
clinically suspected site of infection.
Classification of febrile episodes
Based on clinical, microbiological and radiological data and
blinded of PCT results, the etiology of fever was classified on day 2
after onset of fever according to standard definitions of the
International Immunocompromised Host Society (ICHS) and to
the PCT manufacturer’s recommendations derived from previous
PCT studies: i) microbiologically documented infection with
(MDIB) or without (MDInB) bacteremia [all MDI were differen-
tiated in those due to coagulase-negative staphylococci (CNS) and
those due to other pathogens (non-CNS)] [9,10,11], ii) clinically
documented infection [CDI, subdivided into superficial (upper
respiratory tract infections, mucositis grade 3, skin and soft tissue
infections, lower urinary tract infections) and deep-seated
infections (lower respiratory tract infections, enterocolitis, muco-
sitis grade 4, hepato-splenic infection, arthritis, osteomyelitis,
upper urinary tract infection, and CNS infection) ] [9,12,13,14],
iii) and fever of unexplained origin (FUO) [15]. Standard
definitions of the focus/i of infection were used in CDI [16].
Mucositis with a WHO score .2 [17] and diarrhea with a
frequency.86/day were considered as CDI [18,19]
Diagnosis of proven, probable or possible invasive fungal disease
(IFD) was based on the definitions of the European Organization
for the Research and Treatment of Cancer-Mycoses Study Group
(EORTC-MSG) [20]. Galactomannan (Platelia, Biorad, France)
and beta-glucan (colorimetric assay, Wako-Maruha, Japan [21])
antigenemias were measured on the same days as the PCT
according to the recommendations of the manufacturers. IFD
were included in the classification of infection as MDIB
(fungemia), MDINB (tissue invasion documented by culture) or
CDI (probable or possible IFD without microbiological evidence).
Antimicrobial therapy
Broad-spectrum beta-lactam antibiotic monotherapy was
started within 1 hour after onset of fever and adjusted after
48 hours according to microbiological results and clinical course,
as recommended [1]. If a patient remained febrile during more
than 3 days despite appropriate antibacterial therapy and/or
presented signs of IFD, antifungal treatment was added as
recommended [1]. Clinical, laboratory, radiological, microbio-
logical and histopathological data and information on antimicro-
bial therapy were prospectively collected. Ongoing antimicrobial
therapy was defined as inappropriate if a microbiologically
documented (e.g. positive culture or PCR) or presumed (e.g.
probable or possible IFD based on EORTC-MSG criteria)
pathogen was not covered [22]. Antibacterial and antifungal
prophylaxis were not used. Antiviral prophylaxis (valacyclovir)
was administered to patients with positive HSV serology during
the neutropenic period.
Procalcitonin measurements
For PCT measurements, 5 ml–blood samples (Li-heparinate,
MonovetteH, Sarstedt, Numbrecht, Germany) were collected for
each FE at the same time as blood cultures at onset of fever (day 0)
and then on day 1, 2, 3, 4, and 7. Follow up after day 7 included
twice-weekly blood sampling until occurrence of a subsequent FE
(measurements according to the above sequence) or discharge (end
of study). The same screening strategy was applied regardless of
the resolution or the persistence of fever. Tubes were centrifuged
during 10 minutes at 3000 rpm.min
21 and stored at 280uC until
processed. PCT was measured by an amplified cryptate emission
technology assay (Kryptor PCT, BRAHMS Diagnostica, Hen-
nigsdorf bei Berlin, Germany) with a functional sensitivity of
60 pg/ml (corresponding to 0.06 ng/ml) and an analytical range
of 60 pg/ml to 5000 pg/ml (i.e. 0.06 to 5 ng/ml). The test’s intra-
and inter-assay coefficient of variation was below 10% [23]
Measurements of PCT were performed in batch at the end of
study and were not available for patients management, nor for
classification of the etiology of fever and localization of infection,
as described above.
Analyses of PCT results for initial diagnostic assessment
of neutropenic fever
Daily PCT values over 7 days after onset of fever were
compared among different etiologies of fever, as defined above.
The time point with the highest PCT value (i.e. peak value) was
considered for analyses of the performance of PCT cut-offs
ranging 100–2000 pg/mL for distinguishing etiologies of fever in
receiver operating characteristic (ROC) curves and by calculation
Procalcitonin in Febrile Neutropenia
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and likelihood ratios, and efficiency. The best PCT cut-off was
defined on the basis of the highest calculated efficiency.
Analyses of PCT results for diagnostic reassessment in
persistent neutropenic fever
PCT kinetics was analyzed in patients with persistent fever
during more than 3 days focusing on the assessment of the
appropriateness of ongoing antimicrobial therapy and the
diagnosis of proven, probable or possible IFD.
Statistical methods
Continuous variables were compared using the Mann-Whitney
(2-group comparison) or Kruskall Wallis (multiple-group com-
parison) non-parametric tests. Categorical variables were com-
pared with the x
2 or Fischer’s exact test, as appropriate. A two-
Table 1. Characteristics of patients and febrile episodes.
Patients 90
Median age (range) 57 (18–76)
Male/Female 55 (61%)/35 (39%)
Acute leukemia/Multiple myeloma or Lymphoma 49 (54%)/41 (46%)
Neutropenic episodes 125
Induction or consolidation for acute leukemia/Autologous HSCT 71 (57%)/54 (43%)
Median days of neutropenia (range) 15 (3–114)
Median days of hospitalization (range) 28 (15–122)
Febrile episodes 194
First/Recurrent febrile episode 133 (69%)/61 (31%)
Antibiotics/No antibiotics ongoing at onset of fever 85 (44%)/109 (56%)
Microbiologically documented infection with bacteremia (MDIB) 45 (23%)
Gram positive 24 (53%)
CNS/non – CNS
1 12/12
Gram negative
2 21 (47%)
Microbiologically documented infection, non-bacteremic (MDInB) 20 (10.5%)
Gram positive 9 (45%)
CNS/non – CNS
3 4/5
Gram negative
4 4 (20%)
Fungi 7 (35%)
Clinically documented infections (CDI) 68 (35%)
Superficial 29 (43%)
Mucositis grade 3 17
Soft tissue 10
Urinary tract infection 2
Deep-seated 39 (57%)
Pneumonia 17
Enterocolitis 11
Mucositis grade 4 8
Hepato-splenic candidiasis 3
Fever of unknown origin (FUO) 61 (31.5%)
Severity of infection
Severe sepsis/septic shock 4 (2.0%)/0 (0%)
Invasive fungal diseases (IFD) 25 (13%)
Proven or probable 20 (80%)
Aspergillosis/Candidiasis 16/4
Possible 5 (20%)
1Streptococcus spp (3), Enterococcus spp (3), other Gram positive (6).
2Escherichia coli (10), Klebsiella oxytoca (2), Klebsiella oxytoca and Citrobacter koseri (3), Enterobacter cloacae (1), Enterobacter cloacae and Moraxella catharralis (1), other
Gram negative (4).
3Clostridium difficile (5).
4Klebsiella pneumoniae (2), Escherichia coli (1), Pseudomonas aeruginosa (1).
HSCT=hematopoietic stem cell transplantation.
CNS=coagulase-negative staphylococci.
doi:10.1371/journal.pone.0018886.t001
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significant. All statistical analyses were performed in Statistical
Package for Social Science (SPSSH 15.0 for Windows, Chicago,
Illinois, USA).
Results
Patients and febrile episodes
194 consecutive febrile episodes (FE) occurred during 125
neutropenic episodes in 90 hematological patients (median 1 FE
per neutropenic episode, range 0–4). 1771 plasma samples were
prospectively collected (median 13 per neutropenic episode, range
4–49). Patient demographics and characteristics of FE are shown
in Table 1.
PCT for initial diagnostic assessment of neutropenic fever
The PCT kinetics over 7 days in FE of different etiologies is
shown in Figure 1, Panel A and B. At fever onset (day 0) no
significant difference in PCT values was observed between
documented infections (MDIB, MDInB, CDI) and FUO. When
subgroups were analyzed, PCT values were significantly higher in
non-CNS MDIB (median 295 pg/mL, range 55–26800) when
compared with all the other etiologies of fever (median 161 pg/
mL, range 30–1751; p,0.05). Among MDIB, PCT at fever onset
was statistically superior in Gram-negative when compared to
Gram-positive bacteremia (median 321 [range 54–14660] vs 129
[57–26800], p=0.004). However, if CNS-MDIB were removed
from this comparison, no statistically significant difference was
observed (median 321 [range 54–14660] vs 150 [73–26800],
p=0.183).
The PCT peak was observed at a median of 2 days after the
onset of fever (range 0–20). When compared with PCT values on
day 2 in FUO (median 204, range 33–771), those in non-CNS
MDIB (2155 pg/ml, range 80–86350; p,0.001), non-CNS
MDInB (336, range 117–12090; p=0.007) and deep-seated CDI
(median 520, range 107–13000; p,0.001) were significantly
higher. However, no significant difference in PCT values on day
2 was observed in CNS MDIB/MDInB and superficial CDI when
compared with FUO (Figure 2). No difference in PCT values in
the various etiologies of fever was observed by stratifying for the
type of chemotherapy regimen, i.e. induction/consolidation
chemotherapy for acute leukemia vs. conditioning chemotherapy
followed by autologous hematopoietic stem cell transplantation
(data not shown).
PCT cut-offs ranging between 100 and 2000 pg/mL were
analyzed on day 2 after the onset of fever. Proportions of PCT
values higher than above cut-offs in different FE etiologies are
reported in Table 2. The performances of these PCT cut-offs for
discriminating different subsets of documented infections from
FUO were calculated. The areas under the ROC curves were
0.695 (all documented infections vs. FUO), 0.803 (non-CNS MDI
and deep-seated CDI vs. FUO), and 0.860 (non-CNS MDIB vs.
FUO), respectively (Figure 3). The best diagnostic efficiency was
observed with a PCT cut-off of 500 pg/mL (Table 3). Efficiency
of PCT was not different in first vs. recurrent FE, in those
occurring with and without ongoing antibiotic therapy at time of
onset of fever (data not shown).
On day 2, 6/59 (10.2%) FUO had a PCT higher than 500 pg/
mL (median 688, range 570–771): these PCT values were
comparable to those observed in deep-seated CDI. FUO with
Figure 1. Median PCT values over 7 days after onset of fever according to the etiology of fever and the localization of infection. 1A:
documented infections (MDIB, MDInB, and CDI) and FUO. 1B: non-CNS MDIB, non-CNS MDInB, CNS MDIB, CNS MDInB, superficial CDI, deep-seated
CDI, and FUO. Day 0=onset of fever, MDIB=microbiologically documented infections with bacteremia, MDInB=microbiologically documented
infections without bacteremia, CDI=clinically documented infections, FUO=fever of unknown origin, CNS=coagulase-negative staphylococci.
doi:10.1371/journal.pone.0018886.g001
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temperature (median 39uC, range 38–39.6, vs. 38.6, 38–40.1) or
duration of fever (median 1.5 day, range 1–12, vs. 1, 1–15). All
patients responded to antibiotic therapy. Interestingly, although
PCT results were not disclosed in real-time for clinical decisions, the
duration oftherapy waslongerinFUOwithpositive vs. in those with
negative PCT (median 9.5 days, range 5–27, vs. 6, 0–25, p=0.013),
PCT for diagnostic reassessment in persistent
neutropenic fever
Fever persisted during more than 3 days in 63/194 (32%) FE
(20 MDI, 31 CDI, 12 FUO). Antimicrobial therapy was
inappropriate in 24/63 (38%) cases (18 invasive fungal diseases
[IFD], 5 bacterial and 1 viral infections due to VZV reactivation).
The proportion of persistently febrile episodes with inappropriate
antimicrobial therapy was significantly higher in those with a PCT
higher than 500 pg/mL (13/24, 54%) when compared with those
with a PCT lower than 500 pg/mL (11/39, 28%; p=0.039).
IFD according to EORTC-MSG criteria were diagnosed in 21/
63 (33%) episodes of persistent fever (18 invasive aspergillosis: 1
proven, 12 probable, 5 possible; 3 invasive candidiasis: 1 proven, 2
probable). Figure 4 shows the PCT kinetics in persistent fever
beyond day 3 comparing IFD (median PCT 560 pg/ml, range 32–
11950) with non-fungal FE (median PCT 299 pg/ml, range 0–
166200 [p=0.001 vs. IFD]). A delayed PCT peak (increase
.500 pg/ml beyond 3 days after fever onset) was observed in 17/
21 (81%, median 1196 pg/ml, range 524–11950) IFD with
persistent fever when compared with 18/42 (43%) non-fungal FE
with persistent fever (p=0.004). The performance of a delayed PCT
peak for the diagnosis of proven, probable or possible IFD in
persistent fever during more than 3 days was: sensitivity 81%
(95%CI 57–94%), specificity 57% (95%CI 41–72%), PPV 49%
(95%CI 32–66%), NPV 86% (95%CI 66–95%), positive likelihood
ratio 1.89 (95%CI 1.26–2.84), negative likelihood ratio 0.33 (95%CI
0.13–0.83%), efficiency 0.65. The diagnostic performance of PCT
for proven and probable IFD only (after exclusion of the 5 possible
cases from the analysis) was similar (data not shown). The delayed
PCT increase above 500 pg/mL in IFD with persistent fever
occurred in the same time window as the diagnosis of IFD according
to EORTC-MSG criteria: median 7 days after onset of fever, range
0–21, vs. 8 days, range 4–20 (NS). Delayed PCT increase above
500 pg/mL preceded diagnosis based on EORTC-MSG criteria in
4/17 (24%) IFD cases and was simultaneous in 4/17 (24%).
The patients with IFD received an antifungal therapy within a
median of 4 days (range 0–10) after onset of fever: all survived and
were afebrile at time of discharge. The proportions of patients with
PCT higher than 500 pg/mL and with fever during the course of
IFD are shown in Figure 5. The PCT decrease below 500 pg/
mL preceded the resolution of fever: median 5 days (range 1–23)
vs. 10 days (range 3–22), respectively (p=0.026).
Discussion
The kinetics of PCT was prospectively studied in a large
cohort of febrile neutropenic patients with haematological
Figure 2. Individual PCT values on day 2 after onset of fever
according to etiology of fever and localization of infection.
Each point represents the PCT value in a single febrile episode.
Horizontal bars represent median values in each group. MDIB=micro-
biologically documented infections with bacteremia, MDInB=micro-
biologically documented infections without bacteremia, CDI=clinically
documented infections, FUO=fever of unknown origin, CNS=coagu-
lase-negative staphylococci.
doi:10.1371/journal.pone.0018886.g002
Table 2. PCT on day 2 after onset of fever: positivity at different cut-offs in i) all FE, ii) documented infections (MDIB, MDInB and
CDI), iii) subset including non-CNS MDIB, non-CNS MDInB, and deep-seated CDI, iv) non-CNS MDIB, and v) FUO.
PCT cut-off
(pg/mL) Febrile episodes
Documented infections
(MDI and CDI)
Non-CNS MDIB, non-CNS
MDInB and deep-seated CDI Non-CNS MDIB FUO
n=189* n=130 n=86 n=33 n=59
$100 169 (88.4%) 122 (93.8%) 85 (98.8%) 33 (100%) 47 (79.7%)
$200 123 (65.1%) 93 (71.5%) 73 (84.9%) 31 (93.9%) 30 (50.8%)
$300 95 (50.3%) 77 (59.2%) 62 (72.1%) 28 (84.8%) 18 (30.5%)
$400 81 (42.9%) 67 (51.5%) 58 (67.5%) 26 (78.8%) 14 (23.7%)
$500 62 (32.8%) 56 (43.1%) 48 (55.8%) 23 (69.7%) 6 (10.2%)
$1000 37 (19.6%) 37 (28.5%) 33 (38.4%) 20 (60.6%) 0 (0%)
$2000 23 (12.2%) 23 (17.7%) 22 (25.6%) 17 (51.5%) 0 (0%)
*In 5 febrile episodes (3 documented infections and 2 FUO), blood sampling on day 2 was missing.
MDIB=microbiologically documented infections with bacteremia, MDInB=microbiologically documented infections without bacteremia, CDI=clinically documented
infections, FUO=fever of unknown origin, CNS=coagulase-negative staphylococci.
doi:10.1371/journal.pone.0018886.t002
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infections. A close monitoring of this blood marker at different
time points during the course of a febrile episode and a
thorough analysis of a broad range of PCT cut-offs provided
reliable information on its utility for the initial assessment of the
etiology of fever and for the diagnostic reassessment in persistent
fever.
At onset of fever, PCT was low to undetectable (i.e. below the
threshold of positivity), although the values in non-CNS MDIB
were significantly higher than those in all other etiologies of fever.
A PCT peak was observed in non-CNS MDI and deep-seated
CDI 2 days after the onset of fever, i.e. the time at which a re-
evaluation of the empirical antibacterial therapy based on clinical
course and microbiological results is recommended. The PCT
threshold of 500 pg/mL allowed the best discrimination of these
severe infections from infections due to CNS, superficial infections
or FUO. Interestingly, PCT values higher than this threshold were
observed in a minority of patients with FUO, suggesting that these
FE may have been due to deep-seated bacterial infections with
lacking clinical and microbiological documentation. However, this
could not be demonstrated in these few patients in whom fever was
the only clinical sign suggesting infection and who had received
empirical antibacterial therapy with prompt defervescence.
Monitoring PCT for the diagnostic reassessment in patients with
persistent neutropenic fever lasting more than 3 days revealed that
a delayed PCT peak higher than 500 pg/mL was more frequently
observed in patients receiving inappropriate antimicrobial thera-
py. This finding was true in the majority of cases of IFD and often
Table 3. Diagnostic performance of PCT at the 500 pg/mL cut-off on day 2 after onset of fever in i) documented infections (MDIB,
MDInB and CDI) vs. FUO, ii) non-CNS MDIB, non-CNS MDInB and deep-seated CDI vs. FUO, and iii) non-CNS MDIB vs. FUO.
Etiology of fever
Sensitivity
(95% CI)
Specificity
(95% CI)
PPV
(95% CI)
NPV
(95% CI)
Positive LR
(95% CI)
Negative LR
(95% CI) Efficiency
Documented infections vs. FUO 43.1% (34.5–52.0) 89.8% (78.5–95.8) 90.3% (79.5–96.0) 41.7% (33.2–50.8) 4.26 (1.93–9.27) 0.63 (0.54–0.74) 0.58
Non-CNS MDIB/MDInB and
deep-seated CDI vs. FUO
55.8% (44.7–66.4) 89.8% (78.5–95.8) 88.9% (76.7–95.4) 58.2% (47.4–68.3) 5.49 (2.51–12.00) 0.49 (0.39–0.63) 0.70
Non-CNS MDIB vs. FUO 69.7% (51.1–83.8) 89.8% (78.5–95.8) 79.3% (59.7–91.3) 84.1% (72.3–91.7) 6.85 (3.11–15.12) 0.34 (0.20–0.57) 0.83
PPV=positive predictive value, NPV=negative predictive value, LR=likelihood ratio. 95%CI=95% confidence interval.
MDIB=microbiologically documented infections with bacteremia, MDInB=microbiologically documented infections without bacteremia, CDI=clinically documented
infections, FUO=fever of unknown origin, CNS=coagulase-negative staphylococci.
doi:10.1371/journal.pone.0018886.t003
Figure 3. Receiver operating characteristic curve of PCT on day 2 after onset of fever for diagnosis of A. documented infections
(MDIB, MDInB, CDI) vs. FUO (AUC=0.695); B. non-CNS MDIB, non-CNS MDInB, and deep-seated CDI vs. FUO (AUC=0.803); and C.
non-CNS MDIB vs. FUO (AUC=0.860). MDIB=microbiologically documented infections with bacteremia, MDInB=microbiologically documented
infections without bacteremia, CDI=clinically documented infections, FUO=fever of unknown origin, CNS=coagulase-negative staphylococci,
AUC=area under the receiver operating characteristic curves.
doi:10.1371/journal.pone.0018886.g003
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follow-up PCT decline reflecting the response of IFD to antifungal
therapy significantly anticipated defervescence.
Previous investigations in febrile neutropenic patients have
reported controversial results regarding the performance of PCT
for the initial assessment of the etiology of fever by distinguishing
bacteremia due to pathogens other than CNS from non-
bacteremic infections, and systemic from localized infections or
FUO [9,10,11,12,24,25,26,27,28,29,30].In the present study, the
low PCT values observed at the time of onset of fever in severe
documented infections do not support the use of PCT for the
decision to start or withhold prompt empirical antibacterial
therapy. This finding differs from previous reports in which the
timing of the first PCT measurement was variable [9,12,26,28,29],
i.e. it corresponded either to the onset of fever, the onset of
antimicrobial therapy [11] or the time of blood cultures [10].
Moreover, different types of neutropenic populations (i.e.
hematological vs solid tumors, adults vs children) and delayed
PCT measurements in outpatients vs inpatients may be respon-
sible of the heterogeneity of the results in some studies. On the
other hand, the lack of a reliable diagnostic tool for distinguishing
infections from non-infectious causes of fever when microbiolog-
ical and clinical documentation is lacking, i.e. in FUO, remains a
major issue in management of febrile neutropenic patients. The
utility of PCT for identifying non-documented bacterial infections
in patients with FUO has been suggested by Giamarellos-
Bourboulis et al. who reported higher PCT values in those
responding to antibacterial therapy when compared with those
without response [12]. In the present study, PCT values similar to
those observed in deep-seated CDI were measured on day 2 after
onset of fever in a small subset of patients with FUO, which might
help to identify febrile episodes due to occult severe bacterial
infections.
New findings are provided on the role of PCT for the diagnostic
reassessment in patients with persistent neutropenic fever and
suspected IFD. Few data have been reported in this specific
setting, which represents a major challenge for the clinical
management. Small case series have described controversial
results on the utility of PCT for the diagnosis of IFD
[31,32,33,34]. Some did not report any increase of PCT
concentrations in life-threatening IFD [31,32,33], while others
associated elevated PCT values with poor outcome in IFD [34]. In
5 cases of invasive aspergillosis in allogeneic hematopoietic stem
cell transplant recipients, PCT values exceeding 3000 pg/mL
have been described [35,36]. In contrast with the paucity of
available data in the literature, sequential PCT measurements in a
large number of episodes of persistent fever (n=63), including the
highest number of IFD reported in a PCT study (n=25) are
analyzed in the present investigation. The results suggest that a
delayed PCT peak higher than 500 pg/mL observed beyond 3
Figure 4. PCT kinetics in persistent neutropenic fever during more than 3 days: IFD vs. non-fungal FE. Median PCT values at each time
point are shown.
doi:10.1371/journal.pone.0018886.g004
Figure 5. Percent of patients with PCT .500 pg/ml and fever (temperature .386C) in follow-up of IFD. The T0 for PCT and fever is set
on the time point at which the first positive PCT value (.500 pg/ml) has been documented.
doi:10.1371/journal.pone.0018886.g005
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This blood marker could be combined with the conventional
radiological and microbiological tools for improving and antici-
pating the detection of these life-threatening infections. Moreover,
a PCT decrease to normal levels significantly preceded the
resolution of fever in follow-up of IFD responding to antifungal
therapy. Monitoring PCT may thus help to avoid unnecessary
investigations and modifications of antimicrobial therapy in IFD
with prolonged fever.
In contrast with previous studies, which have shown that
persistently elevated or increasing PCT values predict the outcome
in neutropenic patients with severe sepsis or septic shock, a very
low rate of severe septic complications was observed in the present
investigation. Prompt and appropriate empirical antibacterial
therapy in an epidemiological setting of low bacterial resistance
has probably influenced the PCT kinetics in the majority of
potentially life-threatening infections, thus precluding the evalu-
ation of PCT as a predictor of infection-related severe morbidity
and mortality [9,12,37,38,39]. The lack of data in allogeneic
hematopoietic transplant recipients and the small number of
proven IFD are other limitations of this single-center study.
In conclusion, when recommended clinical, radiological and
microbiological investigations are used, the utility of PCT for the
initial assessment of the etiology of febrile neutropenia is limited.
While PCT measured at the onset of fever cannot be used for the
decision to start or withhold immediate empirical antibacterial
therapy, a PCT value higher than 500 pg/mL in FUO on day 2
might suggest an occult bacterial infection, i.e. with lacking
microbiological and clinical documentation. In contrast, PCT
monitoring is useful for diagnostic reassessment in persistent fever.
A delayed PCT peak higher than 500 pg/mL contributes to the
early diagnosis of invasive fungal disease and PCT decrease in
follow-up promptly reflects response to antifungal therapy when
compared with the slow resolution of fever.
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